- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01122862
Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
August 22, 2013 updated by: GlaxoSmithKline
A Clinical Study to Evaluate the Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
A clinical study to evaluate the effect of a commercial mouth rinse on plaque re-growth
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46825
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Good general and oral health
- At least 20 natural gradable teeth
- Mean plaque score (Turesky Modification of the Quigley Hein Index) of greater than or equal to 2.00 at the first baseline visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 0.12% Chlorhexidine Mouthrinse
Commercially available 0.12% Chlorhexidine mouthrinse
|
commercially available 0.12% chlorhexidine mouthrinse
|
ACTIVE_COMPARATOR: Cosmetic mouthrinse
Commercially available cosmetic mouthrinse
|
Commerically available cosmetic mouthrinse
|
PLACEBO_COMPARATOR: Sterile Water
|
Sterile water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plaque Index of Test Mouth Rinse Versus Sterile Water After Day 4 of Treatment Administration
Time Frame: Day 4 post treatment administration
|
Plaque scores were assessed using Turesky Modification of the Quigley Hein Index and categorized as 0: No plaque; 1: Slight flecks of plaque at the cervical margin of the tooth;2: A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth;3: A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth;4: Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth;5: Plaque covering 2/3 or more of the crown of the tooth.
The interproximal plaque index was calculated by taking the average of plaque scores over the mesiofacial, distofacial, mesiolingual and distolingual surfaces in the upper and lower jaws for a participant.
|
Day 4 post treatment administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plaque Index Score of Test Mouth Rinse Versus Chlorhexidine Mouth Rinse After Day 4 of Treatment Administration
Time Frame: Day 4 post treatment administration
|
Plaque scores were assessed using Turesky Modification of the Quigley Hein Index and categorized as 0: No plaque; 1: Slight flecks of plaque at the cervical margin of the tooth;2: A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth;3: A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth;4: Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth;5: Plaque covering 2/3 or more of the crown of the tooth.
The interproximal plaque index was calculated by taking the average of plaque scores over the mesiofacial, distofacial, mesiolingual and distolingual surfaces in the upper and lower jaws for a participant.
|
Day 4 post treatment administration
|
Plaque Index After 24 Hours of Treatment Administration
Time Frame: Day 1 post treatment administration
|
Plaque scores were assessed using Turesky Modification of the Quigley Hein Index and categorized as 0: No plaque; 1: Slight flecks of plaque at the cervical margin of the tooth;2: A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth;3: A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth;4: Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth;5: Plaque covering 2/3 or more of the crown of the tooth.
The interproximal plaque index was calculated by taking the average of plaque scores over the mesiofacial, distofacial, mesiolingual and distolingual surfaces in the upper and lower jaws for a participant.
|
Day 1 post treatment administration
|
Interproximal Plaque Index After Day 4 of Treatment Administration
Time Frame: Day 4 post treatment administration
|
Plaque scores were assessed using Turesky Modification of the Quigley Hein Index and categorized as 0: No plaque; 1: Slight flecks of plaque at the cervical margin of the tooth;2: A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth;3: A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth;4: Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth;5: Plaque covering 2/3 or more of the crown of the tooth.
The interproximal plaque index was calculated by taking the average of plaque scores over the mesiofacial, distofacial, mesiolingual and distolingual surfaces in the upper and lower jaws for a participant.
|
Day 4 post treatment administration
|
Interproximal Plaque Index After 24 Hours of Treatment Administration
Time Frame: Day 1 post treatment administration
|
Plaque scores were assessed using Turesky Modification of the Quigley Hein Index and categorized as 0: No plaque; 1: Slight flecks of plaque at the cervical margin of the tooth;2: A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth;3: A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth;4: Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth;5: Plaque covering 2/3 or more of the crown of the tooth.
The interproximal plaque index was calculated by taking the average of plaque scores over the mesiofacial, distofacial, mesiolingual and distolingual surfaces in the upper and lower jaws for a participant.
|
Day 1 post treatment administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (ACTUAL)
May 1, 2010
Study Completion (ACTUAL)
May 1, 2010
Study Registration Dates
First Submitted
May 11, 2010
First Submitted That Met QC Criteria
May 11, 2010
First Posted (ESTIMATE)
May 13, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 9, 2013
Last Update Submitted That Met QC Criteria
August 22, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Z36420889
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yuhan CorporationRecruitingAtopic Healthy Subjects | Adult Subjects With Allergic DiseasesKorea, Republic of
-
NeuShen TherapeuticsRecruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Sterile water
-
Woman's Health University Hospital, EgyptUnknown
-
Changi General HospitalUnknownTracheostomy ComplicationSingapore
-
George Washington UniversityCompletedDehydration | Fluid Loss | Extreme ImmaturityUnited States
-
Case Western Reserve UniversityCompletedHypernatremia | Extremely Low Birth Weight InfantsUnited States
-
Nadja Haiden,MDCompletedMeconium Ileus | Very Low Birth Weight Infant
-
Coombe Women and Infants University HospitalCompletedRetinopathy of PrematurityIreland
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Universidad Nacional Autonoma de MexicoHospital General de MexicoUnknownRespiratory Infections in ChildrenMexico
-
Queen Savang Vadhana Memorial Hospital, ThailandNot yet recruitingSmall Bowel Obstruction | Small Bowel Adhesion